CN Bio Raises $21M to Expand Product Portfolio and Support Global Expansion
CN Bio Raises $21M in First Close of Series B Round
CN Bio Raises $21M in Series B Funding
Key Highlights:
- Series B Funding: CN Bio, a provider of microphysiological systems, raised $21 million in the first close of its Series B funding.
- New Investors: Funding includes $10 million from Bayland Capital and $5.5 million from founding shareholder CN Innovations Holdings Ltd.
- Product Portfolio Expansion: Funds will be used to accelerate the development of CN Bio's product portfolio and support global commercial expansion.
CN Bio's Target Market
- Pharmaceutical and Biotech Companies: Drug developers and researchers seeking advanced microphysiological systems for preclinical drug discovery and reducing reliance on animal models.
- Research Institutions: Universities, research centers, and laboratories focused on drug discovery and development.
- Healthcare Providers: Organizations interested in leveraging microphysiological systems for personalized medicine and precision drug testing.
What CN Bio Needs to Buy
- Research and Development Partnerships: Collaborations with pharmaceutical companies and research institutions for advancing microphysiological systems and drug discovery technologies.
- Manufacturing and Supply Chain Solutions: Partnerships with manufacturers to scale production and ensure reliable supply of microphysiological systems.
- Marketing and Sales Support: Services to enhance brand presence, market penetration, and customer acquisition in key global markets.